https://m2.mtmt.hu/ eng 2026-05-31 07:03 JournalArticle 34127894 VALIDATED true 0 false 2026-05-28T06:35:35.090+0000 2024-01-30T09:13:47.460+0000 2023-09-06T08:09:49.977+0000 true 10083204 Herold Zoltán /api/admin/10083204 Admin Zoltán Herold (SE_AOK_SE_1Bel_Onkol_Admin5_HZ, admin) true 2026-02-22T07:37:22.396+0000 2026-02-22T07:37:22.396+0000 2023-10-03T08:08:59.550+0000 true 10083204 Herold Zoltán /api/admin/10083204 Admin Zoltán Herold (SE_AOK_SE_1Bel_Onkol_Admin5_HZ, admin) true 2023-10-09T11:09:26.292+0000 true 10080205 Szalóky-Siki Ágnes /api/admin/10080205 Admin Ágnes Szalóky-Siki (SE_KK_Admin5_SZSA, admin) true Admin 10003133 /api/admin/10003133 Annamária Boros (MTMT Központi admin) Boros Annamária true 10003133 true 2024-07-08T07:27:54.993+0000 true false true 24 24 /api/publicationtype/24 PublicationType Journal Article 1 true 24 JournalArticle true 10000059 Article true 24 24 /api/publicationtype/24 PublicationType Journal Article 1 true 24 JournalArticle /api/subtype/10000059 Szakcikk SubType Article (Journal Article) 101 true 10000059 true 1 /api/category/1 Category Scientific true 1 Barna, Andras Jozsef true true /api/journal/10003252 REVIEWED INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES 1661-6596 1422-0067 true false 10003252 false 10003252 true 1661-6596 1422-0067 Journal FOREIGN 24 18 13684 13684 21 2023 Cancer-related immunity plays a significant role in the outcome of ovarian cancer, but the exact mechanisms are not fully explored. A retrospective, real-life observational study was conducted including 57 advanced ovarian cancer patients. Immunohistochemistry for CD4+, CD8+, and CD45+ was used for assessing tumor-infiltrating immune cells. Furthermore, an immune-related gene expression assay was performed on 12–10 samples from patients with less than and more than 1-year overall survival (OS), respectively. A higher number of CD4+ (p = 0.0028) and CD45+ (p = 0.0221) immune cells within the tumor microenvironment were associated with longer OS of patients. In a multivariate setting, higher CD4+ T cell infiltration predicted longer OS (p = 0.0392). Twenty-three differentially expressed genes—involved in antigen presentation, costimulatory signaling, matrix remodeling, metastasis formation, and myeloid cell activity—were found when comparing the prognostic groups. It was found that tumor-infiltrating immune cell counts are associated with peculiar gene expression patterns and bear prognostic information in ovarian cancer. SOX11 expression emerged and was validated as a predictive marker for OS. Funding 2031108 /api/funding/2031108 (NVKP_16-1-2016-0004) Funder: NKFIH false true Funding 2031109 /api/funding/2031109 (The APC was funded by Semmelweis University) false true true 2023 true true true false true false GOLD 2026-05-28 true https://doi.org/10.3390/ijms241813684 8 0 8 8 0 8 8 8 8 8 8 8 8 8 0 0 8 8 8 8 0 1 1 Folyóiratcikk Journal Article 24 8 Könyvrészlet Chapter in Book 25 0 Könyv Book 23 0 Egyéb konferenciaközlemény Conference paper 31 0 Egyéb konferenciakötet Conference proceedings 32 0 Oltalmi formák Protection forms 26 0 Disszertáció Thesis 28 0 Egyéb Miscellaneous 29 0 Alkotás Achievement 22 0 Kutatási adat Research data 33 0 Folyóiratcikk Journal Article 24 0 0 0 Könyvrészlet Chapter in Book 25 0 0 0 Könyv Book 23 0 0 0 Egyéb konferenciaközlemény Conference paper 31 0 0 0 Egyéb konferenciakötet Conference proceedings 32 0 0 0 Oltalmi formák Protection forms 26 0 0 0 Disszertáció Thesis 28 0 0 0 Egyéb Miscellaneous 29 0 0 0 Alkotás Achievement 22 0 0 0 Kutatási adat Research data 33 0 0 0 2024 0 2 2 2 2 2025 0 4 4 4 4 2026 0 2 2 2 2 D1 false 10030126,10011481 false false false 2023-09-05T08:10:05.995+0000 Belgyógyászati és Hematológiai Klinika (SE / AOK / K); Belgyógyászati és Onkológiai Klinika (SE / AOK / K); Információs Technológiai és Bionikai Kar (PPKE); Patológiai, Igazságügyi és Biztosítási Orvostan... (SE / AOK / I); Semmelweis Egyetem 10 39 5 12 0 true 10003133 Language 10002 /api/language/10002 English Angol English true 2 true PersonAuthorship 109792582 /api/authorship/109792582 Barna, Andras Jozsef [Barna, András József (Szülészet, Nőgyóg...), author] Department of Internal Medicine and Oncology (SU / FM / C) 1 0.083 true false false Author 10090382 /api/author/10090382 András József Barna (Szülészet, Nőgyógyászat) Barna András József true true Barna Andras Jozsef true false false AuthorshipType 1 /api/authorshiptype/1 Author 0 true 0 true false true PersonAuthorship 109792583 /api/authorship/109792583 Herold, Zoltan [Herold, Zoltán (Onkológia, Biosta...), author] Department of Internal Medicine and Oncology (SU / FM / C) 2 0.083 false false false Author 10048640 /api/author/10048640 Zoltán Herold (Onkológia, Biostatisztika, Diabetológia) Herold Zoltán true 10048640 true Herold Zoltan true false false AuthorshipType 1 /api/authorshiptype/1 Author 0 true 0 true false true PersonAuthorship 109792584 /api/authorship/109792584 Acs, Miklos [Ács, Miklós Imre (Sebészet), author] 3 0.083 false false false Author 10082525 /api/author/10082525 Miklós Imre Ács (Sebészet) Ács Miklós Imre true true Acs Miklos true false false AuthorshipType 1 /api/authorshiptype/1 Author 0 true 0 true false true PersonAuthorship 109792585 /api/authorship/109792585 Bazsa, Sandor 4 0.083333336 false false false Bazsa Sandor true false false AuthorshipType 1 /api/authorshiptype/1 Author 0 true 0 true false true PersonAuthorship 109792586 /api/authorship/109792586 Gajdacsi, Jozsef [Gajdácsi, József (Belgyógyászat, ka...), author] Semmelweis University 5 0.083 false false false Author 10083957 /api/author/10083957 József Gajdácsi (Belgyógyászat, kardiológia, egészségbiztosítási szakorvostan) Gajdácsi József true true Gajdacsi Jozsef true false false AuthorshipType 1 /api/authorshiptype/1 Author 0 true 0 true false true PersonAuthorship 109792587 /api/authorship/109792587 Garay, Tamas Marton [Garay, Tamás (sejtbiológia, tum...), author] Információs Technológiai és Bionikai Kar (PPCU); Department of Internal Medicine and Oncology (SU / FM / C) 6 0.083 false false false Author 10030126 /api/author/10030126 Tamás Garay (sejtbiológia, tumorbiológia) Garay Tamás true 10030126 true Garay Tamas Marton true false false AuthorshipType 1 /api/authorshiptype/1 Author 0 true 0 true false true PersonAuthorship 109792588 /api/authorship/109792588 Herold, Magdolna [Herold, Magdolna (Onkológia, Diabet...), author] Department of Internal Medicine and Oncology (SU / FM / C); Belgyógyászati és Hematológiai Klinika (SU / FM / C) 7 0.083 false false false Author 10068026 /api/author/10068026 Magdolna Herold (Onkológia, Diabetológia) Herold Magdolna true true Herold Magdolna true false false AuthorshipType 1 /api/authorshiptype/1 Author 0 true 0 true false true PersonAuthorship 109792589 /api/authorship/109792589 Madaras, Lilla [Madaras, Lilla (patologia), author] Patológiai, Igazságügyi és Biztosítási Orvostan... (SU / FM / I) 8 0.083 false false false Author 10023809 /api/author/10023809 Lilla Madaras (patologia) Madaras Lilla true 10023809 true Madaras Lilla true false false AuthorshipType 1 /api/authorshiptype/1 Author 0 true 0 true false true PersonAuthorship 109792590 /api/authorship/109792590 Muhl, Dorottya [Mühl, Dorottya (Onkológia), author] Department of Internal Medicine and Oncology (SU / FM / C) 9 0.083 false false false Author 10054196 /api/author/10054196 Dorottya Mühl (Onkológia) Mühl Dorottya true 10054196 true Muhl Dorottya true false false AuthorshipType 1 /api/authorshiptype/1 Author 0 true 0 true false true PersonAuthorship 109792591 /api/authorship/109792591 Nagy, Akos 10 0.083333336 false false false Nagy Akos true false false AuthorshipType 1 /api/authorshiptype/1 Author 0 true 0 true false true PersonAuthorship 109792592 /api/authorship/109792592 Szasz, Attila Marcell** ✉ [Szász, Attila Marcell (emlőpatologia), author] Department of Internal Medicine and Oncology (SU / FM / C) 11 0.083 false true true Author 10023803 /api/author/10023803 Attila Marcell Szász (emlőpatologia) Szász Attila Marcell true 10023803 true Szasz Attila Marcell true false false AuthorshipType 1 /api/authorshiptype/1 Author 0 true 0 true false true PersonAuthorship 109792593 /api/authorship/109792593 Dank, Magdolna [Dank, Magdolna (onkológia), author] Department of Internal Medicine and Oncology (SU / FM / C) 12 0.083 false true false Author 10011481 /api/author/10011481 Magdolna Dank (onkológia) Dank Magdolna true 10011481 true Dank Magdolna true false false AuthorshipType 1 /api/authorshiptype/1 Author 0 true 0 true false true PublicationIdentifier 24342111 /api/publicationidentifier/24342111 DOI: 10.3390/ijms241813684 PlainSource 6 /api/publicationsource/6 DOI PublicationSourceType 10001 /api/publicationsourcetype/10001 DOI true true true DOI DOI https://doi.org/@@@ true true 6 true GOLD true IDENTICAL 10.3390/ijms241813684 https://doi.org/10.3390/ijms241813684 false true PublicationIdentifier 24481952 /api/publicationidentifier/24481952 WoS: 001071789700001 PlainSource 1 /api/publicationsource/1 WoS PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true WoS WoS https://www.webofscience.com/wos/woscc/full-record/@@@ true true 1 true IDENTICAL 001071789700001 https://www.webofscience.com/wos/woscc/full-record/001071789700001 true true PublicationIdentifier 24481937 /api/publicationidentifier/24481937 Scopus: 85172861057 PlainSource 3 /api/publicationsource/3 Scopus PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true Scopus Scopus http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-@@@ true true 3 true IDENTICAL 85172861057 http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-85172861057 true true PublicationIdentifier 24438647 /api/publicationidentifier/24438647 PubMed: 37761986 PlainSource 17 /api/publicationsource/17 PubMed PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true PubMed PubMed http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=@@@&dopt=Abstract true true 17 true IDENTICAL 37761986 http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=37761986&dopt=Abstract true true Classification 12215 /api/classification/12215 Clinical medicine true true Classification 12306 /api/classification/12306 Oncology true true Classification 12310 /api/classification/12310 Cancer and its biological basis true true SjrRating 11388415 /api/sjrrating/11388415 sjr:D1 (2023) Scopus - Inorganic Chemistry INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES 1661-6596 1422-0067 7 0.1 journal RatingType 10002 /api/ratingtype/10002 sjr sjr true true ClassificationExternal 1604 /api/classificationexternal/1604 Scopus - Inorganic Chemistry true 1604 true D1 DIRECT true true Reference 44839012 /api/reference/44839012 1. Sung 2021: Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries., CA Cancer J. Clin., 71, p. 209, DOI: 10.3322/caac.21660 1 10.3322/caac.21660 false true Reference 44839013 /api/reference/44839013 2. Burges 2011: Ovarian cancer: Diagnosis and treatment., Dtsch. Ärzteblatt Int., 108, p. 635 2 false true Reference 44839014 /api/reference/44839014 3. Stewart 2019: Ovarian Cancer: An Integrated Review., Semin. Oncol. Nurs., 35, p. 151, DOI: 10.1016/j.soncn.2019.02.001 3 10.1016/j.soncn.2019.02.001 false true Reference 44839015 /api/reference/44839015 4. Mantovani 2008: Cancer-related inflammation., Nature, 454, p. 436, DOI: 10.1038/nature07205 4 10.1038/nature07205 false true Reference 44839016 /api/reference/44839016 5. Coussens 2013: Neutralizing tumor-promoting chronic inflammation: A magic bullet?., Science, 339, p. 286, DOI: 10.1126/science.1232227 5 10.1126/science.1232227 false true Reference 44839017 /api/reference/44839017 6. Jiang 2020: Targeting tumor microenvironment in ovarian cancer: Premise and promise., Biochim. Biophys. Acta BBA-Rev. Cancer, 1873, p. 188361, DOI: 10.1016/j.bbcan.2020.188361 6 10.1016/j.bbcan.2020.188361 false true Reference 44839018 /api/reference/44839018 7. Roxburgh 2012: The role of the in situ local inflammatory response in predicting recurrence and survival in patients with primary operable colorectal cancer., Cancer Treat. Rev., 38, p. 451, DOI: 10.1016/j.ctrv.2011.09.001 7 10.1016/j.ctrv.2011.09.001 false true Reference 44839019 /api/reference/44839019 8. Gavalas 2010: Immune response in ovarian cancer: How is the immune system involved in prognosis and therapy: Potential for treatment utilization., Clin. Dev. Immunol., 2010, p. 791603, DOI: 10.1155/2010/791603 8 10.1155/2010/791603 false true Reference 44839020 /api/reference/44839020 9. Singh 2016: Minireview: Regulatory T Cells and Ovarian Cancer., Immunol. Investig., 45, p. 712, DOI: 10.1080/08820139.2016.1186689 9 10.1080/08820139.2016.1186689 false true Reference 44839021 /api/reference/44839021 10. Zou 2022: Pan-cancer analyses and molecular subtypes based on the cancer-associated fibroblast landscape and tumor microenvironment infiltration characterization reveal clinical outcome and immunotherapy response in epithelial ovarian cancer., Front. Immunol., 13, p. 956224, DOI: 10.3389/fimmu.2022.956224 10 10.3389/fimmu.2022.956224 false true Reference 44839022 /api/reference/44839022 11. Wang 2022: A novel tumor mutational burden-based risk model predicts prognosis and correlates with immune infiltration in ovarian cancer., Front. Immunol., 13, p. 943389, DOI: 10.3389/fimmu.2022.943389 11 10.3389/fimmu.2022.943389 false true Reference 44839023 /api/reference/44839023 12. Jordan 2020: The Capacity of the Ovarian Cancer Tumor Microenvironment to Integrate Inflammation Signaling Conveys a Shorter Disease-free Interval., Clin. Cancer Res., 26, p. 6362, DOI: 10.1158/1078-0432.CCR-20-1762 12 10.1158/1078-0432.CCR-20-1762 false true Reference 44839024 /api/reference/44839024 13. Westergaard, M.C.W., Milne, K., Pedersen, M., Hasselager, T., Olsen, L.R., Anglesio, M.S., Borch, T.H., Kennedy, M., Briggs, G., and Ledoux, S. (2020). Changes in the Tumor Immune Microenvironment during Disease Progression in Patients with Ovarian Cancer. Cancers, 12., DOI: 10.3390/cancers12123828 13 10.3390/cancers12123828 false true Reference 44839025 /api/reference/44839025 14. Khalique, S., Nash, S., Mansfield, D., Wampfler, J., Attygale, A., Vroobel, K., Kemp, H., Buus, R., Cottom, H., and Roxanis, I. (2021). Quantitative Assessment and Prognostic Associations of the Immune Landscape in Ovarian Clear Cell Carcinoma. Cancers, 13., DOI: 10.3390/cancers13153854 14 10.3390/cancers13153854 false true Reference 44839026 /api/reference/44839026 15. James 2022: Adaptive transcriptomic and immune infiltrate responses in the tumor immune microenvironment following neoadjuvant chemotherapy in high grade serous ovarian cancer reveal novel prognostic associations and activation of pro-tumorigenic pathways., Front. Immunol., 13, p. 965331, DOI: 10.3389/fimmu.2022.965331 15 10.3389/fimmu.2022.965331 false true Reference 44839027 /api/reference/44839027 16. Yang 2022: Spatial heterogeneity of infiltrating T cells in high-grade serous ovarian cancer revealed by multi-omics analysis., Cell Rep. Med., 3, p. 100856, DOI: 10.1016/j.xcrm.2022.100856 16 10.1016/j.xcrm.2022.100856 false true Reference 44839028 /api/reference/44839028 17. Meagher 2023: Profiling the immune landscape in mucinous ovarian carcinoma., Gynecol. Oncol., 168, p. 23, DOI: 10.1016/j.ygyno.2022.10.022 17 10.1016/j.ygyno.2022.10.022 false true Reference 44839029 /api/reference/44839029 18. Daabiss 2011: American Society of Anaesthesiologists physical status classification., Indian J. Anaesth., 55, p. 111, DOI: 10.4103/0019-5049.79879 18 10.4103/0019-5049.79879 false true Reference 44839030 /api/reference/44839030 19. Gyorffy 2023: Discovery and ranking of the most robust prognostic biomarkers in serous ovarian cancer., Geroscience, 45, p. 1889, DOI: 10.1007/s11357-023-00742-4 19 10.1007/s11357-023-00742-4 false true Reference 44839031 /api/reference/44839031 20. Kazemi 2022: Tumor-infiltrating lymphocytes for treatment of solid tumors: It takes two to tango?., Front. Immunol., 13, p. 1018962, DOI: 10.3389/fimmu.2022.1018962 20 10.3389/fimmu.2022.1018962 false true Reference 44839032 /api/reference/44839032 21. Lin 2020: Tumor-infiltrating lymphocytes: Warriors fight against tumors powerfully., Biomed. Pharmacother., 132, p. 110873, DOI: 10.1016/j.biopha.2020.110873 21 10.1016/j.biopha.2020.110873 false true Reference 44839033 /api/reference/44839033 22. Xu 2017: Higher Numbers of T-Bet+ Tumor-Infiltrating Lymphocytes Associate with Better Survival in Human Epithelial Ovarian Cancer., Cell. Physiol. Biochem., 41, p. 475, DOI: 10.1159/000456600 22 10.1159/000456600 false true Reference 44839034 /api/reference/44839034 23. Liu 2020: Identification of three molecular subtypes based on immune infiltration in ovarian cancer and its prognostic value., Biosci. Rep., 40, p. BSR20201431, DOI: 10.1042/BSR20201431 23 10.1042/BSR20201431 false true Reference 44839035 /api/reference/44839035 24. Cao 2023: Tumor immune microenvironment changes are associated with response to neoadjuvant chemotherapy and long-term survival benefits in advanced epithelial ovarian cancer: A pilot study., Front. Immunol., 14, p. 1022942, DOI: 10.3389/fimmu.2023.1022942 24 10.3389/fimmu.2023.1022942 false true Reference 44839036 /api/reference/44839036 25. Ovarian Tumor Tissue Analysis Consortium, Goode, E.L., Block, M.S., Kalli, K.R., Vierkant, R.A., Chen, W., Fogarty, Z.C., Gentry-Maharaj, A., Toloczko, A., and Hein, A. (2017). Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer. JAMA Oncol., 3, e173290., DOI: 10.1001/jamaoncol.2017.3290 25 10.1001/jamaoncol.2017.3290 false true Reference 44839037 /api/reference/44839037 26. Barnett 2010: Ovarian cancer tumor infiltrating T-regulatory (T(reg)) cells are associated with a metastatic phenotype., Gynecol. Oncol., 116, p. 556, DOI: 10.1016/j.ygyno.2009.11.020 26 10.1016/j.ygyno.2009.11.020 false true Reference 44839038 /api/reference/44839038 27. Zhang 2021: Lymphocyte and macrophage infiltration in omental metastases indicates poor prognosis in advance stage epithelial ovarian cancer., J. Int. Med. Res., 49, p. 3000605211066245, DOI: 10.1177/03000605211066245 27 10.1177/03000605211066245 false true Reference 44839039 /api/reference/44839039 28. Yang 2018: Clinical significance of the immune microenvironment in ovarian cancer patients., Mol. Omics, 14, p. 341, DOI: 10.1039/C8MO00128F 28 10.1039/C8MO00128F false true Reference 44839040 /api/reference/44839040 29. Wang 2017: Prognostic value of tumor PD-L1 expression combined with CD8(+) tumor infiltrating lymphocytes in high grade serous ovarian cancer., Int. Immunopharmacol., 52, p. 7, DOI: 10.1016/j.intimp.2017.08.017 29 10.1016/j.intimp.2017.08.017 false true Reference 44839041 /api/reference/44839041 30. Devlin 2022: The Tumor Microenvironment of Clear-Cell Ovarian Cancer., Cancer Immunol. Res., 10, p. 1326, DOI: 10.1158/2326-6066.CIR-22-0407 30 10.1158/2326-6066.CIR-22-0407 false true Reference 44839042 /api/reference/44839042 31. Gallego 2021: Tumor infiltrating lymphocytes (TILs) in endometrioid and clear cell ovarian carcinoma: Characterization, association with mismatch repair system deficiency and endometriosis, and prognostic implications., J. Clin. Oncol., 39, p. e17549, DOI: 10.1200/JCO.2021.39.15_suppl.e17549 31 10.1200/JCO.2021.39.15_suppl.e17549 false true Reference 44839043 /api/reference/44839043 32. Santoiemma 2016: Systematic evaluation of multiple immune markers reveals prognostic factors in ovarian cancer., Gynecol. Oncol., 143, p. 120, DOI: 10.1016/j.ygyno.2016.07.105 32 10.1016/j.ygyno.2016.07.105 false true Reference 44839044 /api/reference/44839044 33. Milne, K., Kobel, M., Kalloger, S.E., Barnes, R.O., Gao, D., Gilks, C.B., Watson, P.H., and Nelson, B.H. (2009). Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors. PLoS ONE, 4., DOI: 10.1371/journal.pone.0006412 33 10.1371/journal.pone.0006412 false true Reference 44839045 /api/reference/44839045 34. Pinto 2018: Patient inflammatory status and CD4+/CD8+ intraepithelial tumor lymphocyte infiltration are predictors of outcomes in high-grade serous ovarian cancer., Gynecol. Oncol., 151, p. 10, DOI: 10.1016/j.ygyno.2018.07.025 34 10.1016/j.ygyno.2018.07.025 false true Reference 44839046 /api/reference/44839046 35. Sato 2005: Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer., Proc. Natl. Acad. Sci. USA, 102, p. 18538, DOI: 10.1073/pnas.0509182102 35 10.1073/pnas.0509182102 false true Reference 44839047 /api/reference/44839047 36. Li 2017: The prognostic value of tumor-infiltrating T lymphocytes in ovarian cancer., Oncotarget, 8, p. 15621, DOI: 10.18632/oncotarget.14919 36 10.18632/oncotarget.14919 false true Reference 44839048 /api/reference/44839048 37. Atigan 2021: The relation of CD3, CD4, CD8 and PD-1 expression with tumor type and prognosis in epithelial ovarian cancers., Ginekol. Pol., 92, p. 344, DOI: 10.5603/GP.a2021.0080 37 10.5603/GP.a2021.0080 false true Reference 44839049 /api/reference/44839049 38. Yildirim 2017: Do tumor-infiltrating lymphocytes really indicate favorable prognosis in epithelial ovarian cancer?., Eur. J. Obstet. Gynecol. Reprod. Biol., 215, p. 55, DOI: 10.1016/j.ejogrb.2017.06.005 38 10.1016/j.ejogrb.2017.06.005 false true Reference 44839050 /api/reference/44839050 39. Preston, C.C., Maurer, M.J., Oberg, A.L., Visscher, D.W., Kalli, K.R., Hartmann, L.C., Goode, E.L., and Knutson, K.L. (2013). The ratios of CD8+ T cells to CD4+CD25+ FOXP3+ and FOXP3- T cells correlate with poor clinical outcome in human serous ovarian cancer. PLoS ONE, 8., DOI: 10.1371/journal.pone.0080063 39 10.1371/journal.pone.0080063 false true Reference 44839051 /api/reference/44839051 40. Emens 2021: Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study., J. Natl. Cancer Inst., 113, p. 1005, DOI: 10.1093/jnci/djab004 40 10.1093/jnci/djab004 false true Reference 44839052 /api/reference/44839052 41. Zhang 2003: Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer., N. Engl. J. Med., 348, p. 203, DOI: 10.1056/NEJMoa020177 41 10.1056/NEJMoa020177 false true Reference 44839053 /api/reference/44839053 42. Bound 2022: Improving PARP inhibitor efficacy in high-grade serous ovarian carcinoma: A focus on the immune system., Front. Genet., 13, p. 886170, DOI: 10.3389/fgene.2022.886170 42 10.3389/fgene.2022.886170 false true Reference 44839054 /api/reference/44839054 43. Shah 2008: Intratumoral T cells, tumor-associated macrophages, and regulatory T cells: Association with p53 mutations, circulating tumor DNA and survival in women with ovarian cancer., Gynecol. Oncol., 109, p. 215, DOI: 10.1016/j.ygyno.2008.01.010 43 10.1016/j.ygyno.2008.01.010 false true Reference 44839055 /api/reference/44839055 44. Montfort 2020: Combining measures of immune infiltration shows additive effect on survival prediction in high-grade serous ovarian carcinoma., Br. J. Cancer, 122, p. 1803, DOI: 10.1038/s41416-020-0822-x 44 10.1038/s41416-020-0822-x false true Reference 44839056 /api/reference/44839056 45. Zhang 2015: Infiltration of dendritic cells and T lymphocytes predicts favorable outcome in epithelial ovarian cancer., Cancer Gene Ther., 22, p. 198, DOI: 10.1038/cgt.2015.7 45 10.1038/cgt.2015.7 false true Reference 44839057 /api/reference/44839057 46. Zhang 2021: Spatial cytotoxic and memory T cells in tumor predict superior survival outcomes in patients with high-grade serous ovarian cancer., Cancer Med., 10, p. 3905, DOI: 10.1002/cam4.3942 46 10.1002/cam4.3942 false true Reference 44839058 /api/reference/44839058 47. Li 2022: The Immune Subtype Contributes to Distinct Overall Survival for Ovarian Cancer Patients With Platinum-Based Adjuvant Therapy., Front. Immunol., 13, p. 872991, DOI: 10.3389/fimmu.2022.872991 47 10.3389/fimmu.2022.872991 false true Reference 44839059 /api/reference/44839059 48. Gill 2021: Tumor immune microenvironment in brain metastases from gynecologic malignancies., Cancer Immunol. Immunother., 70, p. 2951, DOI: 10.1007/s00262-021-02909-4 48 10.1007/s00262-021-02909-4 false true Reference 44839060 /api/reference/44839060 49. Arend 2018: Molecular Response to Neoadjuvant Chemotherapy in High-Grade Serous Ovarian Carcinoma., Mol. Cancer Res., 16, p. 813, DOI: 10.1158/1541-7786.MCR-17-0594 49 10.1158/1541-7786.MCR-17-0594 false true Reference 44839061 /api/reference/44839061 50. Heong 2021: A multi-ethnic analysis of immune-related gene expression signatures in patients with ovarian clear cell carcinoma., J. Pathol., 255, p. 285, DOI: 10.1002/path.5769 50 10.1002/path.5769 false true Reference 44839062 /api/reference/44839062 51. Rocconi, R.P., Stanbery, L., da Silva, L.M., Barrington, R.A., Aaron, P., Manning, L., Horvath, S., Wallraven, G., Bognar, E., and Walter, A. (2021). Long-Term Follow-Up of Gemogenovatucel-T (Vigil) Survival and Molecular Signals of Immune Response in Recurrent Ovarian Cancer. Vaccines, 9., DOI: 10.3390/vaccines9080894 51 10.3390/vaccines9080894 false true Reference 44839063 /api/reference/44839063 52. Weberpals 2021: Tumor genomic, transcriptomic, and immune profiling characterizes differential response to first-line platinum chemotherapy in high grade serous ovarian cancer., Cancer Med., 10, p. 3045, DOI: 10.1002/cam4.3831 52 10.1002/cam4.3831 false true Reference 44839064 /api/reference/44839064 53. Yin, M., Lu, C., Zhou, H., Liu, Q., and Yang, J. (2023). Differential molecular pathway expression according to chemotherapeutic response in ovarian clear cell carcinoma. BMC Womens Health, 23., DOI: 10.1186/s12905-023-02420-1 53 10.1186/s12905-023-02420-1 false true Reference 44839065 /api/reference/44839065 54. Mairinger 2019: Digital Immune-Related Gene Expression Signatures In High-Grade Serous Ovarian Carcinoma: Developing Prediction Models For Platinum Response., Cancer Manag. Res., 11, p. 9571, DOI: 10.2147/CMAR.S219872 54 10.2147/CMAR.S219872 false true Reference 44839066 /api/reference/44839066 55. Choi 2020: Differences in immune-related gene expressions and tumor-infiltrating lymphocytes according to chemotherapeutic response in ovarian high-grade serous carcinoma., J. Ovarian Res., 13, p. 65, DOI: 10.1186/s13048-020-00667-y 55 10.1186/s13048-020-00667-y false true Reference 44839067 /api/reference/44839067 56. Jordan 2020: mRNA expression in low grade serous ovarian cancer: Results of a nanoString assay in a diverse population., Gynecol. Oncol., 159, p. 554, DOI: 10.1016/j.ygyno.2020.08.030 56 10.1016/j.ygyno.2020.08.030 false true Reference 44839068 /api/reference/44839068 57. Salgado 2015: The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: Recommendations by an International TILs Working Group 2014., Ann. Oncol., 26, p. 259, DOI: 10.1093/annonc/mdu450 57 10.1093/annonc/mdu450 false true Reference 44839069 /api/reference/44839069 58. Bankhead 2017: QuPath: Open source software for digital pathology image analysis., Sci. Rep., 7, p. 16878, DOI: 10.1038/s41598-017-17204-5 58 10.1038/s41598-017-17204-5 false true Reference 44839070 /api/reference/44839070 59. Bhattacharya 2021: An approach for normalization and quality control for NanoString RNA expression data., Brief. Bioinform., 22, p. bbaa163, DOI: 10.1093/bib/bbaa163 59 10.1093/bib/bbaa163 false true Reference 44839071 /api/reference/44839071 60. Risso 2014: Normalization of RNA-seq data using factor analysis of control genes or samples., Nat. Biotechnol., 32, p. 896, DOI: 10.1038/nbt.2931 60 10.1038/nbt.2931 false true Reference 44839072 /api/reference/44839072 61. Love 2014: Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2., Genome Biol., 15, p. 550, DOI: 10.1186/s13059-014-0550-8 61 10.1186/s13059-014-0550-8 false true Reference 44839073 /api/reference/44839073 62. Wickham, H., Navarro, D., and Pedersen, T.L. (2023, June 01). ggplot2: Elegant Graphics for Data Analysis (3e). Available online: https://ggplot2-book.org/. 62 false true Reference 44839074 /api/reference/44839074 63. Gu 2016: Complex heatmaps reveal patterns and correlations in multidimensional genomic data., Bioinformatics, 32, p. 2847, DOI: 10.1093/bioinformatics/btw313 63 10.1093/bioinformatics/btw313 false true /api/publication/34127894 Barna Andras Jozsef et al. High Tumor-Infiltrating Lymphocyte Count Is Associated with Distinct Gene Expression Profile and Longer Patient Survival in Advanced Ovarian Cancer. (2023) INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES 1661-6596 1422-0067 24 18<div class="JournalArticle Publication long-list"> <div class="authors"> <img title="Forrásközlemény" style="float: left" src="/frontend/resources/grid/publication-core-icon.png"> <img title="Idézőközlemény" style="float: left" src="/frontend/resources/grid/publication-citation-icon.png"> <div class="autype autype0"> <span class="author-name" mtid="10090382"><a href="/gui2/?type=authors&mode=browse&sel=10090382" target="_blank">Barna Andras Jozsef (<span class="authorship-author-name">Barna András József</span> <span class="authorAux-mtmt"> Szülészet, Nőgyógyászat</span>) </a> </span> <span class="author-affil"><span title="Semmelweis University">SU</span>/<span title="Faculty of Medicine">FM</span>/<span title="Clinical">C</span>/Department of Internal Medicine and Oncology</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10048640"><a href="/gui2/?type=authors&mode=browse&sel=10048640" target="_blank">Herold Zoltan (<span class="authorship-author-name">Herold Zoltán</span> <span class="authorAux-mtmt"> Onkológia, Biostatisztika, Diabetológia</span>) </a> </span> <span class="author-affil"><span title="Semmelweis University">SU</span>/<span title="Faculty of Medicine">FM</span>/<span title="Clinical">C</span>/Department of Internal Medicine and Oncology</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10082525"><a href="/gui2/?type=authors&mode=browse&sel=10082525" target="_blank">Acs Miklos (<span class="authorship-author-name">Ács Miklós Imre</span> <span class="authorAux-mtmt"> Sebészet</span>) </a> </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Bazsa Sandor </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10083957"><a href="/gui2/?type=authors&mode=browse&sel=10083957" target="_blank">Gajdacsi Jozsef (<span class="authorship-author-name">Gajdácsi József</span> <span class="authorAux-mtmt"> Belgyógyászat, kardiológia, egészségbiztosítási...</span>) </a> </span> <span class="author-affil">Semmelweis University</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10030126"><a href="/gui2/?type=authors&mode=browse&sel=10030126" target="_blank">Garay Tamas Marton (<span class="authorship-author-name">Garay Tamás</span> <span class="authorAux-mtmt"> sejtbiológia, tumorbiológia</span>) </a> </span> <span class="author-affil"><span title="Pázmány Péter Catholic University">PPCU</span>/Információs Technológiai és Bionikai Kar; <span title="Semmelweis University">SU</span>/<span title="Faculty of Medicine">FM</span>/<span title="Clinical">C</span>/Department of Internal Medicine and Oncology</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10068026"><a href="/gui2/?type=authors&mode=browse&sel=10068026" target="_blank">Herold Magdolna (<span class="authorship-author-name">Herold Magdolna</span> <span class="authorAux-mtmt"> Onkológia, Diabetológia</span>) </a> </span> <span class="author-affil"><span title="Semmelweis University">SU</span>/<span title="Faculty of Medicine">FM</span>/<span title="Clinical">C</span>/Department of Internal Medicine and Oncology; <span title="Semmelweis University">SU</span>/<span title="Faculty of Medicine">FM</span>/<span title="Clinical">C</span>/Belgyógyászati és Hematológiai Klinika</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10023809"><a href="/gui2/?type=authors&mode=browse&sel=10023809" target="_blank">Madaras Lilla (<span class="authorship-author-name">Madaras Lilla</span> <span class="authorAux-mtmt"> patologia</span>) </a> </span> <span class="author-affil"><span title="Semmelweis University">SU</span>/<span title="Faculty of Medicine">FM</span>/<span title="Instituties">I</span>/Patológiai, Igazságügyi és Biztosítási Orvostani Intézet</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10054196"><a href="/gui2/?type=authors&mode=browse&sel=10054196" target="_blank">Muhl Dorottya (<span class="authorship-author-name">Mühl Dorottya</span> <span class="authorAux-mtmt"> Onkológia</span>) </a> </span> <span class="author-affil"><span title="Semmelweis University">SU</span>/<span title="Faculty of Medicine">FM</span>/<span title="Clinical">C</span>/Department of Internal Medicine and Oncology</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Nagy Akos </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10023803"><a href="/gui2/?type=authors&mode=browse&sel=10023803" target="_blank">Szasz Attila Marcell^** ✉ (<span class="authorship-author-name">Szász Attila Marcell</span> <span class="authorAux-mtmt"> emlőpatologia</span>) </a> </span> <span class="author-affil"><span title="Semmelweis University">SU</span>/<span title="Faculty of Medicine">FM</span>/<span title="Clinical">C</span>/Department of Internal Medicine and Oncology</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10011481"><a href="/gui2/?type=authors&mode=browse&sel=10011481" target="_blank">Dank Magdolna (<span class="authorship-author-name">Dank Magdolna</span> <span class="authorAux-mtmt"> onkológia</span>) </a> </span> <span class="author-affil"><span title="Semmelweis University">SU</span>/<span title="Faculty of Medicine">FM</span>/<span title="Clinical">C</span>/Department of Internal Medicine and Oncology</span> </div> </div> <div class="title"><a href="/gui2/?mode=browse&params=publication;34127894" target="_blank">High Tumor-Infiltrating Lymphocyte Count Is Associated with Distinct Gene Expression Profile and Longer Patient Survival in Advanced Ovarian Cancer</a></div> <div> <span class="journal-title">INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES</span> <span class="journal-issn">(<a target="_blank" href="https://portal.issn.org/resource/ISSN/1661-6596">1661-6596</a> <a target="_blank" href="https://portal.issn.org/resource/ISSN/1422-0067">1422-0067</a>)</span>: <span class="journal-volume">24</span> <span class="journal-issue">18</span> <span class="page"> Paper 13684. 21 p. </span> <span class="year">(2023)</span> </div> <div class="pub-footer"> <span class="language" xmlns="http://www.w3.org/1999/html">Language: English | </span> <span class="identifiers"> <span class="id identifier oa_GOLD" title=" Gold "> <a style="color:blue" title="10.3390/ijms241813684" target="_blank" href="https://doi.org/10.3390/ijms241813684"> DOI </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="001071789700001" target="_blank" href="https://www.webofscience.com/wos/woscc/full-record/001071789700001"> WoS </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="85172861057" target="_blank" href="http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-85172861057"> Scopus </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="37761986" target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=37761986&dopt=Abstract"> PubMed </a> </span> </span> <OnlyViewableByAuthor><div class="ratings"> <div class="journal-subject">Journal subject: Scopus - Inorganic Chemistry&nbsp;&nbsp;&nbsp;Rank:&nbsp;D1</div> <div class="journal-subject">Journal subject: Scopus - Organic Chemistry&nbsp;&nbsp;&nbsp;Rank:&nbsp;D1</div> <div class="journal-subject">Journal subject: Scopus - Spectroscopy&nbsp;&nbsp;&nbsp;Rank:&nbsp;D1</div> <div class="journal-subject">Journal subject: Scopus - Computer Science Applications&nbsp;&nbsp;&nbsp;Rank:&nbsp;Q1</div> <div class="journal-subject">Journal subject: Scopus - Medicine (miscellaneous)&nbsp;&nbsp;&nbsp;Rank:&nbsp;Q1</div> <div class="journal-subject">Journal subject: Scopus - Physical and Theoretical Chemistry&nbsp;&nbsp;&nbsp;Rank:&nbsp;Q1</div> <div class="journal-subject">Journal subject: Scopus - Catalysis&nbsp;&nbsp;&nbsp;Rank:&nbsp;Q2</div> <div class="journal-subject">Journal subject: Scopus - Molecular Biology&nbsp;&nbsp;&nbsp;Rank:&nbsp;Q2</div> </div></OnlyViewableByAuthor> <div class="publication-citation" style="margin-left: 0.5cm;"> <span title="" class="citingPub-count">Citing papers: 8</span> | Independent citation: 8 | Self citation: 0 | Unknown citation: 0 | Number of citations in WoS: 8 | Number of citations in Scopus:&nbsp;8 | WoS/Scopus assigned:&nbsp;8 | Number of citations with DOI:&nbsp;8 </div> <div class="publication-citation"> <a target="_blank" href="/api/publication?cond=citations.related;eq;34127894&sort=publishedYear,desc&sort=title"> Number of cited publications: 1 </a> </div> <div class="mtid"><span class="long-pub-mtid">Publication: 34127894</span> | <span class="status-data status-VALIDATED"> Validated </span> Core Citing | <span class="type-subtype">Journal Article ( Article ) </span> | <span class="pub-category">Scientific</span> | <span class="publication-sourceOfData">kézi felvitel</span> </div> <div class="funder"> (NVKP_16-1-2016-0004) Funder: NRDIO, (The APC was funded by Semmelweis University) </div> <div class="lastModified">Last Modified: 2024.01.30. 10:13 Viktória Sifter (PPKE ITK admin 5) </div> <div class="lockedBy">Centrally managed 2024.07.08. 09:27 Annamária Boros (MTMT Központi admin) </div> </div></div>